Anti-Mu Opioid Receptor antibody [UMB3] - C-terminal
- RabMAb
- Recombinant
- 20ul selling size
- What is this?
4
(3 Reviews)
|
(53 Publications)
Anti-Mu Opioid Receptor antibody [UMB3] - C-terminal (ab134054) is a rabbit monoclonal antibody detecting Mu Opioid Receptor in Western Blot.
- Biophysical QC for unrivalled batch-batch consistency
- Over 40 publications
View Alternative Names
MOR1, OPRM1, Mu-type opioid receptor, M-OR-1, MOR-1, Mu opiate receptor, Mu opioid receptor, MOP, hMOP
- WB
Unknown
Western blot - Anti-Mu Opioid Receptor antibody [UMB3] - C-terminal (AB134054)
All lanes:
Western blot - Anti-Mu Opioid Receptor antibody [UMB3] - C-terminal (ab134054) at 1/1000 dilution
Lane 1:
Mu Opioid Receptor transfected HEK-293 (Human epithelial cell line from embryonic kidney) lysate at 10 µg
Lane 2:
HEK-293T cell lysate at 10 µg
Secondary
All lanes:
HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 45 kDa
false
Related conjugates and formulations (2)
-
Anti-Mu Opioid Receptor antibody [UMB3] - Low endotoxin, Azide free
-
Anti-Mu Opioid Receptor antibody [UMB3] - BSA and Azide free
Reactivity data
Product details
What is this antibody validated in?
Anti-Mu Opioid Receptor antibody [UMB3] - C-terminal (ab134054) is a rabbit recombinant monoclonal antibody and is validated for use in Western Blot (WB). What is the molecular weight of Mu Opioid Receptor?
Anti-Mu Opioid Receptor [UMB3] - C-terminal (ab134054) specifically detects a band for Mu Opioid Receptor (UniProt: P35372) at a molecular weight of 45kDa.
Trusted by the scientific community
Anti-Mu Opioid Receptor [UMB3] - C-terminal (ab134054) was first used in a scientific publication in 2012 and has been cited over 40 times in peer-reviewed journals.
Trial sizes available!
Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 10µl. Discover our selection of trial-size antibodies.
Other related products
We have a range of other formats of antibody clone [UMB3] also available for your convenience: ab134054, Carrier free - ab227067, Carrier free - ab271900
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
The Mu Opioid Receptor plays an essential role in modulating pain perception and response to opioids. It interacts predominantly with inhibitory G-proteins reducing neuronal excitability by decreasing cAMP levels and increasing potassium ion conductance. MORs are part of opioid receptor family which also includes delta and kappa receptors forming a complex regulatory system for the opioid signaling pathways. These receptors also modulate the release of neurotransmitters like GABA and dopamine.
Pathways
Signaling through the Mu Opioid Receptor integrates with the analgesic and reward pathways. It is important in the pain modulation pathway where it influences the perception of and response to pain stimuli. MORs interact with proteins such as adenylate cyclase and beta-arrestin which mediate desensitization and down-regulation processes. This interaction can also modulate the activity of dopamine pathways further linking MOR to reward and addiction mechanisms.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (53)
Recent publications for all applications. Explore the full list and refine your search
Alzheimer's research & therapy 17:35 PubMed39893485
2025
Applications
Unspecified application
Species
Unspecified reactive species
The Journal of comparative neurology 532:e70003 PubMed39656141
2024
Applications
Unspecified application
Species
Unspecified reactive species
Nature communications 15:8856 PubMed39402067
2024
Applications
Unspecified application
Species
Unspecified reactive species
BMC gastroenterology 24:23 PubMed38191294
2024
Applications
Unspecified application
Species
Unspecified reactive species
The Journal of neuroscience : the official journal of the Society for Neuroscience 44: PubMed38124021
2023
Applications
Unspecified application
Species
Unspecified reactive species
Current biology : CB 33:5011-5022.e6 PubMed37879332
2023
Applications
Unspecified application
Species
Unspecified reactive species
Biosensors & bioelectronics 241:115625 PubMed37708685
2023
Applications
Unspecified application
Species
Unspecified reactive species
Nature communications 14:5632 PubMed37704594
2023
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in molecular neuroscience 16:1207911 PubMed37389091
2023
Applications
Unspecified application
Species
Unspecified reactive species
Communications biology 6:419 PubMed37061609
2023
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com